Pharm-Olam

Pharm-Olam, founded in 1994, is a specialized biotechnology firm providing extensive research and development services. As a contract research organization (CRO), the company focuses on delivering high-quality clinical research, supporting drug development from early-stage molecules to late-phase trials. Their core competencies include robust data management, strategic risk management planning, and comprehensive clinical trial services designed to accelerate therapeutic advancements across various medical fields. Pharm-Olam's expertise is particularly noted in areas such as oncology, rare diseases, and vaccine development, leveraging a forward-thinking approach to tackle complex scientific challenges. The company operates with a global footprint, managing 12 locations to serve its client base effectively.

Employing between 500 and 1,000 professionals, Pharm-Olam possesses the capacity to manage diverse and demanding clinical development programs. Their service suite encompasses critical aspects like trial design optimization, dedicated sponsor support, and stringent data protection protocols throughout the research lifecycle. The organization is committed to advancing treatments in therapeutic areas including allergy, hematology, and other specialized fields. For detailed information on the personnel driving these efforts, interested parties can refer to Meet Pharm-Olam's team. This team structure supports mid-size to global clients in achieving rapid progress in bringing novel therapies to market.

With a reported revenue of $21.8M, Pharm-Olam maintains a significant presence in the competitive CRO market. Their product and service offerings are broad, covering all facets of clinical trial execution, quality assurance, and strategic consulting. Pharm-Olam is dedicated to facilitating the entire drug development continuum, from initial molecule identification and characterization to the intricate design and executionView more...